Mohini Rajasagi

1.4k total citations
16 papers, 951 citations indexed

About

Mohini Rajasagi is a scholar working on Oncology, Radiology, Nuclear Medicine and Imaging and Immunology. According to data from OpenAlex, Mohini Rajasagi has authored 16 papers receiving a total of 951 indexed citations (citations by other indexed papers that have themselves been cited), including 10 papers in Oncology, 5 papers in Radiology, Nuclear Medicine and Imaging and 5 papers in Immunology. Recurrent topics in Mohini Rajasagi's work include Cancer Immunotherapy and Biomarkers (8 papers), Monoclonal and Polyclonal Antibodies Research (5 papers) and Chronic Lymphocytic Leukemia Research (4 papers). Mohini Rajasagi is often cited by papers focused on Cancer Immunotherapy and Biomarkers (8 papers), Monoclonal and Polyclonal Antibodies Research (5 papers) and Chronic Lymphocytic Leukemia Research (4 papers). Mohini Rajasagi collaborates with scholars based in United States, Israel and Australia. Mohini Rajasagi's co-authors include Catherine J. Wu, Vladimir Brusić, Nir Hacohen, Edward F. Fritsch, Gad Getz, Sachet A. Shukla, Kristian Cibulskis, Carrie Sougnez, Patrick A. Ott and Jonathan Stevens and has published in prestigious journals such as Journal of Clinical Oncology, Nature reviews. Cancer and Blood.

In The Last Decade

Mohini Rajasagi

15 papers receiving 942 citations

Peers

Mohini Rajasagi

IMMUN

ONCOL

RNMI

Isaac Kriley United States

David R. Kroeger Canada

Matilde D’Asaro Italy

Harry Klip Netherlands

Anne Marie Asemissen Germany

Aruna Mani United States

Max M. Wattenberg United States

Sviatoslav M. Kendall United States

Kristine Rinn United States

Samantha Bucktrout United States

Isaac Kriley United States

Mohini Rajasagi

744 ×1.1

IMMUN

983 ×1.6

ONCOL

297 ×0.9

84 ×0.6

112 ×0.9

RNMI

Citations per year, relative to Mohini Rajasagi Mohini Rajasagi (= 1×) peers Isaac Kriley

Countries citing papers authored by Mohini Rajasagi

Since Specialization

Citations

This map shows the geographic impact of Mohini Rajasagi's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Mohini Rajasagi with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Mohini Rajasagi more than expected).

Fields of papers citing papers by Mohini Rajasagi

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Mohini Rajasagi. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Mohini Rajasagi. The network helps show where Mohini Rajasagi may publish in the future.

Co-authorship network of co-authors of Mohini Rajasagi

This figure shows the co-authorship network connecting the top 25 collaborators of Mohini Rajasagi. A scholar is included among the top collaborators of Mohini Rajasagi based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Mohini Rajasagi. Mohini Rajasagi is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

16 of 16 papers shown

Morales‐Barrera, Rafael, Thomas Powles, Mustafa Özgüroğlu, et al.. (2022). Association of TMB and PD-L1 with efficacy of first-line pembrolizumab (pembro) or pembro + chemotherapy (chemo) versus chemo in patients (pts) with advanced urothelial carcinoma (UC) from KEYNOTE-361.. Journal of Clinical Oncology. 40(6_suppl). 540–540. 3 indexed citations

Shapira‐Frommer, Ronnie, Ruth Perets, Mark Voskoboynik, et al.. (2022). Abstract CT508: Safety and efficacy of vibostolimab (vibo) plus pembrolizumab (pembro) in patients (pts) with cervical cancer naive to PD-1/PD-L1 inhibitors. Cancer Research. 82(12_Supplement). CT508–CT508. 8 indexed citations

Mileham, Kathryn F., Mark Voskoboynik, Sun Young Rha, et al.. (2022). PD-3 Phase 1 trial of vibostolimab plus pembrolizumab for PD-1/PD-L1 inhibitor-naive advanced gastric cancer: The KEYVIBE-001 trial. Annals of Oncology. 33. S240–S240. 5 indexed citations

Perets, Ruth, Martin Gutierrez, Sun Young Rha, et al.. (2022). Abstract CT180: Safety and efficacy of vibostolimab (vibo) plus pembrolizumab (pembro) and coformulation of vibo/pembro in ovarian cancer naive to PD-1/PD-L1 inhibitors. Cancer Research. 82(12_Supplement). CT180–CT180. 2 indexed citations

Ahn, M-J., Jiaxin Niu, Dongwook Kim, et al.. (2020). 1400P Vibostolimab, an anti-TIGIT antibody, as monotherapy and in combination with pembrolizumab in anti-PD-1/PD-L1-refractory NSCLC. Annals of Oncology. 31. S887–S887. 26 indexed citations

Bellmunt, Joaquim, Ronald de Wit, Yves Fradet, et al.. (2020). 747P Association of TMB with efficacy of pembrolizumab (pembro) in patients (pts) with advanced urothelial cancer (UC): Results from KEYNOTE-045 and KEYNOTE-052. Annals of Oncology. 31. S580–S581. 5 indexed citations

Grivas, Petros, Arjun Vasant Balar, Jacqueline Vuky, et al.. (2020). 744P Association between gene expression signatures (sigs) and pembrolizumab (pembro) efficacy in patients (pts) with advanced urothelial cancer (UC). Annals of Oncology. 31. S577–S578. 2 indexed citations

Niu, Jiaxin, Adnan Nagrial, Mark Voskoboynik, et al.. (2020). 1410P Safety and efficacy of vibostolimab, an anti-TIGIT antibody, plus pembrolizumab in patients with anti-PD-1/PD-L1-naive NSCLC. Annals of Oncology. 31. S891–S892. 19 indexed citations

Bachireddy, Pavan, Ute Burkhardt, Mohini Rajasagi, & Catherine J. Wu. (2015). Haematological malignancies: at the forefront of immunotherapeutic innovation. Nature reviews. Cancer. 15(4). 201–215. 59 indexed citations

10.

Shukla, Sachet A., Michael S. Rooney, Mohini Rajasagi, et al.. (2015). Comprehensive analysis of cancer-associated somatic mutations in class I HLA genes. Nature Biotechnology. 33(11). 1152–1158. 408 indexed citations

11.

Shukla, Sachet A., Mohini Rajasagi, Philip M. Dixon, et al.. (2015). Abstract 1093: Sensitive detection of somatic mutations in class I HLA genes reveals enrichment for functional events in cancer. Cancer Research. 75(15_Supplement). 1093–1093.

12.

Rajasagi, Mohini, Sachet A. Shukla, Edward F. Fritsch, et al.. (2014). Systematic identification of personal tumor-specific neoantigens in chronic lymphocytic leukemia. Blood. 124(3). 453–462. 233 indexed citations

13.

Fritsch, Edward F., Mohini Rajasagi, Patrick A. Ott, et al.. (2014). HLA-Binding Properties of Tumor Neoepitopes in Humans. Cancer Immunology Research. 2(6). 522–529. 151 indexed citations

14.

Rajasagi, Mohini, Sachet A. Shukla, Edward F. Fritsch, et al.. (2013). Tumor Neoantigens Are Abundant Across Cancers. Blood. 122(21). 3265–3265. 2 indexed citations

15.

Hainz, Ursula, Ute Burkhardt, Kristen E. Stevenson, et al.. (2012). CD40L-Tri, a novel formulation of recombinant human CD40L that effectively activates B cells. Cancer Immunology Immunotherapy. 62(2). 347–357. 26 indexed citations

16.

Rajasagi, Mohini, Derin B. Keskin, Wandi Zhang, et al.. (2012). Systematic Identification of Personal Mutated Tumor-Specific Neoantigens in CLL. Blood. 120(21). 954–954. 2 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact